| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.200503-344OC |
| P698 | PubMed publication ID | 16272450 |
| P2093 | author name string | John J Lipuma | |
| Alexander J McAdam | |||
| Leslie A Kalish | |||
| Donald Goldmann | |||
| Craig Gerard | |||
| Gail Potter-Bynoe | |||
| David A Waltz | |||
| Mark Dovey | |||
| P2860 | cites work | Predictive 5-year survivorship model of cystic fibrosis | Q30481059 |
| Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis | Q30659487 | ||
| Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. | Q30931157 | ||
| Burkholderia and emerging pathogens in cystic fibrosis | Q30998871 | ||
| Burkholderia cepacia in cystic fibrosis: novel Australian cluster strain without accelerated respiratory deterioration | Q34235969 | ||
| Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group | Q34291682 | ||
| Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia | Q35532451 | ||
| Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre | Q35534997 | ||
| Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. | Q35536317 | ||
| Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis | Q35557791 | ||
| Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak | Q36572695 | ||
| Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis | Q39586003 | ||
| Pseudomonas cepacia infection in cystic fibrosis: an emerging problem | Q40829590 | ||
| Burkholderia cepacia: medical, taxonomic and ecological issues | Q41260421 | ||
| Determinants of mortality from cystic fibrosis in Canada, 1970-1989. | Q43698922 | ||
| Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. | Q44291562 | ||
| Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome | Q44445035 | ||
| Burkholderia cepacia in cystic fibrosis. Variable disease course. | Q50653659 | ||
| 'Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization. | Q52858667 | ||
| Evidence of transmission ofBurkholderia cepacia,Burkholderia multivoransandBurkholderia dolosaamong persons with cystic fibrosis | Q54743699 | ||
| Infection withBurkholderia cepaciaComplex Genomovars in Patients with Cystic Fibrosis: Virulent Transmissible Strains of Genomovar III Can ReplaceBurkholderia multivorans | Q57265587 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| Burkholderia dolosa | Q4999010 | ||
| P304 | page(s) | 421-425 | |
| P577 | publication date | 2005-11-04 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis | |
| P478 | volume | 173 |
| Q60928130 | A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease |
| Q47653778 | A putative lateral flagella of the cystic fibrosis pathogen Burkholderia dolosa regulates swimming motility and host cytokine production. |
| Q36238452 | An Oxygen-Sensing Two-Component System in the Burkholderia cepacia Complex Regulates Biofilm, Intracellular Invasion, and Pathogenicity |
| Q24186416 | Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation |
| Q24198135 | Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation |
| Q33857479 | Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. |
| Q42286592 | Assessment of fluorescent in situ hybridization and PCR-based methods for rapid identification of Burkholderia cepacia complex organisms directly from sputum samples. |
| Q34924879 | Biocide susceptibility of the Burkholderia cepacia complex |
| Q92652695 | Burkholderia cepacia Complex Species Differ in the Frequency of Variation of the Lipopolysaccharide O-Antigen Expression During Cystic Fibrosis Chronic Respiratory Infection |
| Q37064461 | Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology |
| Q38283021 | Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years' experience |
| Q36158785 | Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy? |
| Q46707042 | Can health-related quality of life predict survival in adults with cystic fibrosis? |
| Q56920001 | Chance and necessity in the evolution of a bacterial pathogen |
| Q34754801 | Chemistry and biology of the potent endotoxin from a Burkholderia dolosa clinical isolate from a cystic fibrosis patient. |
| Q38378454 | Clinical and in vitro evidence for the antimicrobial therapy in Burkholderia cepacia complex infections. |
| Q35864774 | Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis. |
| Q34491552 | Clinical significance of microbial infection and adaptation in cystic fibrosis |
| Q34607873 | Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro |
| Q55881299 | Cystic fibrosis |
| Q33637302 | Entry of Burkholderia organisms into respiratory epithelium: CFTR, microfilament and microtubule dependence |
| Q36895659 | Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection |
| Q36771148 | Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis |
| Q35455438 | Gene expression profiling of Burkholderia cenocepacia at the time of cepacia syndrome: loss of motility as a marker of poor prognosis? |
| Q37691811 | Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures. |
| Q38710198 | Immune Recognition of the Epidemic Cystic Fibrosis Pathogen Burkholderia dolosa |
| Q92977261 | Impact of clonally-related Burkholderia contaminans strains in two patients attending an Italian cystic fibrosis centre: a case report |
| Q33576059 | Impact of multidrug-resistant organisms on patients considered for lung transplantation |
| Q42206103 | Infection prevention and control guideline for cystic fibrosis: 2013 update |
| Q37149666 | Intensive care management of the patient with cystic fibrosis |
| Q36658777 | Lung transplantation for cystic fibrosis: results, indications, complications, and controversies |
| Q33909370 | Monitoring clinical and microbiological evolution of a cystic fibrosis patient over 26 years: experience of a Brazilian CF Centre. |
| Q37780043 | Mucoid and nonmucoid Burkholderia cepacia complex bacteria in cystic fibrosis infections |
| Q36670892 | Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. |
| Q33874056 | Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis |
| Q30426714 | Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. |
| Q37373050 | Recent advances in the microbiology of respiratory tract infection in cystic fibrosis |
| Q38181712 | Respiratory infections in patients with cystic fibrosis undergoing lung transplantation |
| Q42166892 | Revised approach for identification of isolates within the Burkholderia cepacia complex and description of clinical isolates not assigned to any of the known genomovars |
| Q34746975 | Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patients |
| Q81596022 | Segregation is good for patients with cystic fibrosis |
| Q28066704 | Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis |
| Q35244339 | Swimming motility in a longitudinal collection of clinical isolates of Burkholderia cepacia complex bacteria from people with cystic fibrosis. |
| Q30419079 | Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection |
| Q27316052 | The Salmonella SPI2 effector SseI mediates long-term systemic infection by modulating host cell migration |
| Q33825634 | The changing microbial epidemiology in cystic fibrosis |
| Q35163645 | The evolving dynamics of the microbial community in the cystic fibrosis lung |
| Q38453923 | The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis |
| Q39542270 | Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy |
| Q36101044 | Understanding the Pathogenicity of Burkholderia contaminans, an Emerging Pathogen in Cystic Fibrosis |
| Q36779226 | Update in cystic fibrosis 2006 |
| Q46098724 | Update in cystic fibrosis 2008. |
Search more.